Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion.
Nishijima M, Ido K, Okayama Y, Okamura H, Kuno M, Makuuchi Y, Nishimoto M, Nakashima Y, Koh H, Nakamae M, Hino M, Nakamae H. Nishijima M, et al. Among authors: makuuchi y. Int J Hematol. 2024 Nov;120(5):645-650. doi: 10.1007/s12185-024-03839-4. Epub 2024 Aug 30. Int J Hematol. 2024. PMID: 39210087
Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.
Nakane T, Okamura H, Tagaito Y, Koh S, Yoshimura T, Makuuchi Y, Nanno S, Nakamae M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H. Nakane T, et al. Among authors: makuuchi y. Int J Hematol. 2019 Dec;110(6):736-742. doi: 10.1007/s12185-019-02743-6. Epub 2019 Sep 27. Int J Hematol. 2019. PMID: 31560116 Clinical Trial.
Increasing numbers of CD19 + CD24highCD38high regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia.
Hayashi T, Nakamae H, Takeda S, Nakashima Y, Koh H, Nishimoto M, Okamura H, Nanno S, Makuuchi Y, Kuno M, Nakamae M, Hirose A, Hino M. Hayashi T, et al. Among authors: makuuchi y. Int J Hematol. 2021 Nov;114(5):580-590. doi: 10.1007/s12185-021-03192-w. Epub 2021 Jul 26. Int J Hematol. 2021. PMID: 34309815
A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H, Nakane T, Okamura H, Koh H, Nakashima Y, Hirose A, Nakamae M, Nishimoto M, Kuno M, Makuuchi Y, Harada N, Takakuwa T, Hino M. Nakamae H, et al. Among authors: makuuchi y. Int J Hematol. 2022 Jan;115(1):77-86. doi: 10.1007/s12185-021-03228-1. Epub 2021 Sep 29. Int J Hematol. 2022. PMID: 34586587 Clinical Trial.
Correction to: A phase II study of post‑transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA‑matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H, Nakane T, Okamura H, Koh H, Nakashima Y, Hirose A, Nakamae M, Nishimoto M, Kuno M, Makuuchi Y, Harada N, Takakuwa T, Hino M. Nakamae H, et al. Among authors: makuuchi y. Int J Hematol. 2022 Jan;115(1):146. doi: 10.1007/s12185-021-03252-1. Int J Hematol. 2022. PMID: 34724154 No abstract available.
Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.
Takemura K, Nakamae M, Okamura H, Sakatoku K, Ido K, Makuuchi Y, Kuno M, Takakuwa T, Hirose A, Nishimoto M, Nakashima Y, Koh H, Igarashi K, Kubota H, Hino M, Nakamae H. Takemura K, et al. Among authors: makuuchi y. Ann Hematol. 2024 May;103(5):1705-1715. doi: 10.1007/s00277-024-05685-0. Epub 2024 Mar 18. Ann Hematol. 2024. PMID: 38494552
Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K, Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Hirose A, Nakamae M, Nishimoto M, Nakashima Y, Koh H, Hino M, Nakamae H. Tazoe K, et al. Among authors: makuuchi y. Ann Hematol. 2024 Jun;103(6):2059-2072. doi: 10.1007/s00277-024-05772-2. Epub 2024 Apr 25. Ann Hematol. 2024. PMID: 38662207
Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation.
Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Koh S, Yoshimura T, Nanno S, Nakamae M, Hirose A, Nakashima Y, Nakane T, Hino M, Nakamae H. Nishimoto M, et al. Among authors: makuuchi y. Br J Clin Pharmacol. 2017 Sep;83(9):2000-2007. doi: 10.1111/bcp.13303. Epub 2017 May 24. Br J Clin Pharmacol. 2017. PMID: 28407449 Free PMC article.
67 results